Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment

Table 2 Revised original pre-treatment scoring system[10]

Variable	Result	Points	Variable	Result	Points
Gender	Female	+2	HLA	DR3 or DR4	+1
AP:AST (or ALT) ratio	> 3	-2	Immune disease	Thyroiditis, colitis, others	+2
	< 1.5	+2
γ-globulin or IgG level above normal	> 2.0	+3	Other markers	Anti-SLA, actin, LC1, pANCA	+2
	1.5-2.0	+2
	1.0-1.5	+1
	< 1.0	0
ANA, SMA, or anti-LKM1 titers	> 1:80	+3	Histological features	Interface hepatitis	+3
	1:80	+2		Plasmacytic	+1
	1:40	+1		Rosettes	+1
	< 1:40	0		None of above	-5
				Biliary changes	-3
				Other features	-3
AMA	Positive	-4	Treatment response	Complete	+2
				Relapse	+3
Viral markers	Positive	-3
	Negative	+3
Drugs	Yes	-4	Pretreatment aggregate score
	No	+1	Definite diagnosis		> 15
			Probable diagnosis		10-15
Alcohol	< 25 g/d	+2	Post-treatment aggregate score
	> 60 g/d	-2	Definite diagnosis		> 17
			Probable diagnosis		12-17

AP: AST (or ALT) ratio: Ratio of alkaline phosphatase level to aspartate or alanine aminotransferase level; Anti-SLA: Antibodies to soluble liver antigen; Anti-LC1: Antibodies to liver cytosol type 1; pANCA: Perinuclear anti-neutrophil cytoplasmic antibodies; IgG: Immunoglobulin G; ANA: Antinuclear antibodies; SMA: Smooth muscle antibodies; Anti-LKM1: Antibodies to liver/kidney type 1; AMA: Antimitochondrial antibodies; HLA: Human leukocyte antigen.